Primary aldosteronism was common among patients with hypertension in a primary care setting, highlighting the need for active screening.

Being proactive and participating in an evidence-based program can save lives! Falls are the leading cause of fatal and nonfatal ...

A community-based remote patient monitoring (RPM) program was associated with significant reduction in blood pressure in Medicare patients with stage 2 hypertension, highlighting the potential ...

Idorsia Pharmaceuticals has claimed FDA approval for aprocitentan as a treatment for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that indication.

Lorundrostat effectively reduced 24-hour blood pressure in patients with well-treated, uncontrolled hypertension in the phase ...

The novel aldosterone inhibitor works, but longer-term safety data are needed before the drug might be approved.

Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ETCompany ParticipantsBryan Giraudo - COO & CFOFaheem Hasnain ...

Synhale Therapeutics Inc. (Synhale), a virtual, clinical-stage biotech company committed to transforming Pulmonary Hypertension (PH), announced the acquisition of Telaglenastat (CB-839), the ...

A mineralocorticoid receptor antagonist that blocks excess aldosterone and reduces fluid volumes, spironolactone is the ...

Myles Borne is empowered. At birth, Myles Borne was diagnosed with persistent pulmonary hypertension of the newborn, a ...

You need to get more exercise and move more.” Have you heard a similar phrase from your doctor? If so, you’re not alone. The ...